Poolbeg Pharma (LON:POLB) Trading Up 12.1% – Here’s Why

Poolbeg Pharma PLC (LON:POLB) rose 12.1% during mid-day trading on Tuesday . The stock traded as high as GBX 6.56 and last traded at GBX 6.56. Approximately 1,736,688 shares traded hands during mid-day trading, an increase of 36% from the average daily volume of 1,280,718 shares. The stock had previously closed at GBX 5.85.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a report on Tuesday, May 26th.

Poolbeg Pharma Stock Performance

The stock has a market cap of £46.25 million, a PE ratio of -6.98 and a beta of 1.78. The business has a 50 day moving average price of GBX 4.60 and a two-hundred day moving average price of GBX 4.35.

Poolbeg Pharma (LON:POLB) last released its earnings results on Tuesday, April 28th. The company reported GBX (0.94) EPS for the quarter. As a group, research analysts anticipate that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.